CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 855 enrolled
Drug / intervention
Tazarotene Cream 0.05% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02886702
NCT02886702Phase 3Completed
CompareCT.gov

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Fougera Pharmaceuticals Inc.·interventional·Posted Sep 1, 2016·Updated Aug 29, 2018

In Brief

A Phase 3 clinical trial evaluating Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 855 participants across 30 sites.

Detailed Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 1, 2016
Enrollment StartSep 19, 2016
Primary CompletionAug 2, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.8 years ago

Interventions

Tazarotene Cream 0.05%drug

Tazarotene Cream 0.05% to cover only the lesions with a thin film.

TAZORAC® (tazarotene) Cream 0.05%drug

TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.

Placebodrug

Placebo (vehicle of the test product) to cover only the lesions with a thin film.